Phase 3 study evaluating the safety and efficacy of oteseconazole in the treatment of recurrent vulvovaginal candidiasis and acute vulvovaginal candidiasis infections.
- DOI
- 10.1016/j.ajog.2022.07.023
- Published
- 2022 Dec
- Container
- American journal of obstetrics and gynecology
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.ajog.2022.07.023,
title = {Phase 3 study evaluating the safety and efficacy of oteseconazole in the treatment of recurrent vulvovaginal candidiasis and acute vulvovaginal candidiasis infections.},
author = {Martens MG and Maximos B and Degenhardt T and Person K and Curelop S and Ghannoum M and Flynt A and Brand SR},
year = {2022},
journal = {American journal of obstetrics and gynecology},
doi = {10.1016/j.ajog.2022.07.023},
url = {https://doi.org/10.1016/j.ajog.2022.07.023}
}RIS
TY - JOUR TI - Phase 3 study evaluating the safety and efficacy of oteseconazole in the treatment of recurrent vulvovaginal candidiasis and acute vulvovaginal candidiasis infections. AU - Martens MG AU - Maximos B AU - Degenhardt T AU - Person K AU - Curelop S AU - Ghannoum M AU - Flynt A AU - Brand SR PY - 2022 JO - American journal of obstetrics and gynecology DO - 10.1016/j.ajog.2022.07.023 UR - https://doi.org/10.1016/j.ajog.2022.07.023 ER -
APA
MG, M., B, M., T, D., K, P., S, C., M, G., A, F., & SR, B. (2022). Phase 3 study evaluating the safety and efficacy of oteseconazole in the treatment of recurrent vulvovaginal candidiasis and acute vulvovaginal candidiasis infections.. American journal of obstetrics and gynecology. https://doi.org/10.1016/j.ajog.2022.07.023
Source records
- pubmed · retrieved 2026-09-27T07:50:09.341Z